Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(57.1%)
Phase 2
3(42.9%)
7Total
N/A(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07298577Not ApplicableEnrolling By Invitation

Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer

Role: collaborator

NCT06713798Phase 2Withdrawn

Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Role: collaborator

NCT00183898Phase 2Unknown

Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

Role: collaborator

NCT00125021Phase 2Completed

Tarceva and Capecitabine for Pancreatic Cancer

Role: collaborator

NCT00002330Not ApplicableCompleted

A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Role: lead

NCT00002134Not ApplicableCompleted

A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis

Role: lead

NCT00002015Not ApplicableCompleted

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

Role: lead

All 7 trials loaded